Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CK-1827452 in Stable Heart Failure
NCT00941681Phase 2Completed
- Sponsor
- Cytokinetics
- Start
- Apr 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of omecamtiv mecarbil in heart failure (HF) (3 cohorts), sponsored by Cytokinetics. Primary endpoints: Maximum Plasma Concentration (Cmax) at Day 10, Time to Maximum Plasma Concentration (Tmax) at Day 10 and 1 more. Started Apr 2009; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00941681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941681.